E&P Capital initiates on Australian Clinical Labs with 'positive'

Healius

15/01/2024 18:54

** Analysts at E&P Capital initiate coverage on Australian
Clinical Labs (ACL)  ACL.AX  with 'positive' recommendation
    ** Gives Price Target of A$3.70/share
    ** Says ACL is preferred stock among Aussie healthcare
services firms
    ** Brokerage sits 3% above market consensus estimates for
FY26 on ACL assuming co is able to generate greater margin
expansion
    ** Adds ACL is cheap as compared to its peers and is gaining
market share from rival Healius  HLS.AX  
    ** Three of five analysts rate the stock "buy" or higher and
two "hold"; their median PT is A$3.60 – LSEG data
    ** Stock has risen 2.4% this year, as of last close 

 (Reporting by Rishav Chatterjee in Bengaluru)
 ((Rishav.Chatterjee@thomsonreuters.com;))